NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Rituximab

Countries: Germany

This observational study will assess the therapeutic efficiency, treatment schedules, handling procedures, and the safety profile of rituximab in routine care in participants with CLL.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* CLL requiring treatment
* Participants receiving a chemotherapy in combination with rituximab (decision taken by doctor prior to and independent from inclusion in this non-interventional study)
* After this trial started, an amendment to the study protocol was introduced, adding a further inclusion criterion: Comorbidities according to cumulative illness rating scale (CIRS) score greater than (\>) 6 and/or creatinine clearance less than (\<) 70 milliliters per minute (mL/min)

Exclusion Criteria:

* Participants with contraindication to rituximab treatment

Locations (1)

Frechen, Germany